Biomoda Technology Could Help Resolve Issues Over Lung Cancer Early Screening

Albuquerque, NM March 24, 2007 — A recent study published in the Journal of the American Medical Association questions the efficacy of CT scans for the early detection of lung cancer and its relationship to improved mortality rates. This is further evidence that the first-step, non-invasive screening test developed by Biomoda will be an essential tool for more accurate detection and treatment of lung cancer, said John Cousins, President of Biomoda, Inc. (www.biomoda.com) of Albuquerque, NM, maker of early lung cancer detection testing and other cancer diagnostic technology. Biomoda, Inc. trades on NASDAQ's OTC Bulletin Board under the ticker symbol "BMOD".

“Ninety million Americans are smokers or former smokers, and they're all at risk of lung cancer, the deadliest cancer of all,” said Cousins. “Biomoda’s technology can detect lung cancer at its earliest stages, and because the test is simple and non-invasive, it can continue to be used to monitor the development or growth of cancer throughout any course of treatment.”

“As a diagnostic tool for localizing tumors, CT Scanning is unrivaled,” said Cousins. “However radiology does have limitations so far as frequency of testing in a monitoring application to keep tabs on the dynamics of tumor growth or if cancer is spreading. That is where our test can work as a complementary tool to monitor cancer dynamics and recurrence. Our assay can be used in conjunction with CT scans as a front end test as part of a tiered diagnostic schema to more efficiently allocate CT scanning resources. Our assay can detect cancer at the cellular level even before tumors manifest themselves, making it a true early detection assay.”

"I have no doubt that early screening saves lives. The question raised by this new study, and the need that Biomoda can meet with its technology, is the accuracy and ability of diagnostic testing to find the cancers that are life threatening. CT scans may not be perfect, but we believe that in conjunction with Biomoda’s sputum test, we are much closer to an accurate and effective diagnostic tool that will save lives,” said Cousins.

Biomoda's technology is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. Cancerous cells glow red under fluorescent light to allow detection under a microscope. The patented technology, a non-invasive cytology based assay, is designed for cancer screening at an early stage of large populations at a reasonable cost.
"Safe Harbor" Statement: This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are naturally subject to uncertainty and changes in circumstances. Actual results may vary materially from expectations contained herein. Biomoda is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.